Interpretation of the Guidelines for the Assessment and Clinical Practice of Behavioral and Psychological Symptoms of Dementia 2025

doi:10.3969/j.issn.1004-583X.2025.05.001

Abstract

Abstract:

Currently, more than 55 million people suffer from dementia worldwide. Alzheimer's disease (AD) is the most common diagnostic cause of dementia, accounting for 50%-70% of all dementia cases. In March 2025, the Canadian Coalition for Seniors' Mental Health (CCSHM) released the Guidelines for the Assessment and Clinical Practice of Behavioral and Psychological Symptoms of Dementia 2025, targeting on the assessment and management of BPSD in AD patients. The present article focused on the five major symptoms of BPSD, including agitation, depression, anxiety, mental symptoms and potential risk sexual behavior manifestations, as well as the the reduction of antipsychotics and psychotropic drugs. Through interpreting key suggestions in the guideline, three aspects of diagnostic criteria, evaluation methods and treatment measures were discussed to provide references for clinical treatment of BPSD and optimizing the whole-process management of BPSD symptoms in AD patients.

Key words: Alzheimer's disease, behavioral and psychological symptoms of dementia, dementia, consensus development conference

CLC Number:

R745.7

Gao Yan, Qu Shuo, Li Yang, Qiu Huiqing, He Sha, Ma Xiaowei. Interpretation of the Guidelines for the Assessment and Clinical Practice of Behavioral and Psychological Symptoms of Dementia 2025[J]. Clinical Focus, 2025, 40(5): 389-393.

Add to citation manager EndNote|Ris|BibTeX

URL: http://www.lchc.cn/EN/10.3969/j.issn.1004-583X.2025.05.001

http://www.lchc.cn/EN/Y2025/V40/I5/389

Figures/Tables 1

References 28

[1]	王刚, 齐金蕾, 刘馨雅, 等. 中国阿尔茨海默病报告2024[J]. 诊断学理论与实践, 2024, 23(3):219-256.
[2]	Dartigues JF. Alzheimer's disease: A global challenge for the 21st century[J]. Lancet Neurol, 2009, 8(12):1082-1083. doi: 10.1016/S1474-4422(09)70298-4 pmid: 19909903
[3]	2023 Alzheimer's disease facts and figures[J]. Alzheimers Dement, 2023, 19(4):1598-1695. doi: 10.1002/alz.13016 pmid: 36918389
[4]	Hachinski V. The comprehensive, customized, cost-effective approach (CCCAP) to prevention of dementia[J]. Alzheimers Dement, 2022, 18(8):1565-1568. doi: 10.1002/alz.12586 pmid: 35103397
[5]	Lyketsos CG, Lopez O, Jones B, et al. Prevalence of neuropsychiatric symptoms in dementia and mild cognitive impairment: Results from the cardiovascular health study[J]. Jama, 2002, 288(12):1475-1483.
[6]	Kazui H, Yoshiyama K, Kanemoto H, et al. Differences of behavioral and psychological symptoms of dementia in disease severity in four major dementias[J]. PLoS One, 2016, 11(8): e0161092.
[7]	Watt JA, Porter J, Tavilsup P, et al. Guideline recommendations on behavioral and psychological symptoms of dementia: A systematic review[J]. J Am Med Dir Assoc, 2024, 25(5):837-846.e21.
[8]	Hatch S, Seitz DP, Bruneau MA, et al. The Canadian Coalition for Seniors' Mental Health Canadian clinical practice guidelines for assessing and managing behavioural and psychological symptoms of dementia (BPSD)[J]. Can Geriatr J, 2025, 28(1):91-102.
[9]	Cummings J, Pinto L C, Cruz M, et al. Criteria for psychosis in major and mild neurocognitive disorders: International Psychogeriatric Association (IPA) consensus clinical and research definition[J]. Am J Geriatr Psychiatry, 2020, 28(12):1256-1269. doi: 10.1016/j.jagp.2020.09.002 pmid: 32958332
[10]	Singh A, Gupta I, Wright SM, et al. Outcomes among hospitalized patients with dementia and behavioral disturbances when physical restraints are introduced[J]. J Am Geriatr Soc, 2023, 71(9):2886-2892.
[11]	Evans D, Wood J, Lambert L. Patient injury and physical restraint devices: A systematic review[J]. J Adv Nurs, 2003, 41(3):274-282. pmid: 12581115
[12]	Grant JE, Mohan SN. Treatment of agitation and aggression in four demented patients using ECT[J]. J ect, 2001, 17(3):205-209. pmid: 11528314
[13]	Davies SJ, Burhan AM, Kim D, et al. Sequential drug treatment algorithm for agitation and aggression in Alzheimer's and mixed dementia[J]. J Psychopharmacol, 2018, 32(5):509-523. doi: 10.1177/0269881117744996 pmid: 29338602
[14]	Porsteinsson AP, Drye LT, Pollock BG, et al. Effect of citalopram on agitation in Alzheimer disease: The CitAD randomized clinical trial[J]. Jama, 2014, 311(7):682-691. doi: 10.1001/jama.2014.93 pmid: 24549548
[15]	Rapoport MJ, Van Reekum R, Freedman M, et al. Relationship of psychosis to aggression, apathy and function in dementia[J]. Int J Geriatr Psychiatry, 2001, 16(2):123-130.
[16]	Teng E, Ringman JM, Ross LK, et al. Diagnosing depression in Alzheimer disease with the national institute of mental health provisional criteria[J]. Am J Geriatr Psychiatry, 2008, 16(6):469-477. doi: 10.1097/JGP.0b013e318165dbae pmid: 18515691
[17]	Alexopoulos GS, Abrams RC, Young RC, et al. Cornell Scale for Depression in Dementia[J]. Biol Psychiatry, 1988, 23(3):271-284.
[18]	Klimova B, Toman J, Kuca K. Effectiveness of the dog therapy for patients with dementia-a systematic review[J]. BMC Psychiatry, 2019, 19(1):276. doi: 10.1186/s12888-019-2245-x pmid: 31492131
[19]	Olsen C, Pedersen I, Bergland A, et al. Effect of animal-assisted interventions on depression, agitation and quality of life in nursing home residents suffering from cognitive impairment or dementia: A cluster randomized controlled trial[J]. Int J Geriatr Psychiatry, 2016, 31(12):1312-1321.
[20]	First MB. Diagnostic and statistical manual of mental disorders, 5th edition, and clinical utility[J]. J Nerv Ment Dis, 2013, 201(9):727-729. doi: 10.1097/NMD.0b013e3182a2168a pmid: 23995026
[21]	Sukhawathanakul P, Crizzle A, Tuokko H, et al. Psychotherapeutic interventions for dementia: A systematic review[J]. Can Geriatr J, 2021, 24(3):222-236.
[22]	Van Der Steen JT, Smaling HJ, Van Der Wouden JC, et al. Music-based therapeutic interventions for people with dementia[J]. Cochrane Database Syst Rev, 2018, 7(7): Cd003477.
[23]	Knight C, Alderman N, Johnson C, et al. The St Andrew's Sexual Behaviour Assessment (SASBA): Development of a standardised recording instrument for the measurement and assessment of challenging sexual behaviour in people with progressive and acquired neurological impairment[J]. Neuropsychol Rehabil, 2008, 18(2):129-159. doi: 10.1080/09602010701822381 pmid: 18350412
[24]	Moncrieff J, Gupta S, Horowitz MA. Barriers to stopping neuroleptic (antipsychotic) treatment in people with schizophrenia, psychosis or bipolar disorder[J]. Ther Adv Psychopharmacol, 2020, 10: 2045125320937910.
[25]	Van Dis EAM, Van Veen SC, Hagenaars MA, et al. Long-term outcomes of cognitive behavioral therapy for anxiety-related disorders: A systematic review and meta-analysis[J]. JAMA Psychiatry, 2020, 77(3):265-273. doi: 10.1001/jamapsychiatry.2019.3986 pmid: 31758858
[26]	López-López JA, Davies SR, Caldwell DM, et al. The process and delivery of CBT for depression in adults: A systematic review and network meta-analysis[J]. Psychol Med, 2019, 49(12):1937-1947. doi: 10.1017/S003329171900120X pmid: 31179960
[27]	Hazell CM, Hayward M, Cavanagh K, et al. A systematic review and meta-analysis of low intensity CBT for psychosis[J]. Clin Psychol Rev, 2016, 45:183-192. doi: 10.1016/j.cpr.2016.03.004 pmid: 27048980
[28]	Lutgens D, Gariepy G, Malla A. Psychological and psychosocial interventions for negative symptoms in psychosis: systematic review and meta-analysis[J]. Br J Psychiatry, 2017, 210(5):324-332. doi: 10.1192/bjp.bp.116.197103 pmid: 28302699

良好实践声明	一般原则
良好实践声明1	为规范BPSD的结构化评估及临床管理路径,建议为临床医护人员与非专业照护者提供多维度教育培训。
良好实践声明2	征得患者或患者家属的知情同意。
良好实践声明3	将患者价值观、个体化照护目标及预计恢复前景等核心要素纳入结构化评估体系。
良好实践声明4	回顾痴呆症的潜在病因、痴呆症的分期(轻度、中度、重度)及特征性BPSD,包括发生频率、持续时间、严重程度及其他可能相关的危险因素。
良好实践声明5	对BPSD潜在生物学诱因进行系统评估,包括谵妄状态评估、综合医学评估及精神病史采集、药物使用情况审查、物质使用情况调查、听力与视力功能评估、疼痛程度评估及其他相关生物医学因素分析。
良好实践声明6	对痴呆症患者的人格特征进行全面审查,包括性别、性取向、语言、种族、民族、文化背景、外伤史、宗教或精神信仰以及其他相关因素,从而深度解析BPSD的潜在影响因素,为评估和管理BPSD提供依据。
良好实践声明7	构建基于生物-心理-社会医学模式的BPSD全面评估体系。
良好实践声明8	在与痴呆症患者、护理人员或医疗保健提供者交流时,采用以人为本的表达方式,并根据受众特点,用通俗易懂的语言具体描述BPSD。
良好实践声明9	建议对所有BPSD患者单独实施社会心理干预,或结合药物治疗进行综合治疗。
良好实践声明10	针对特定BPSD(行为与心理症状),选择并调整安全有效的干预措施。
良好实践声明11	定期评估BPSD管理计划的有效性,并根据动态评估指标对干预措施进行优化调整。

良好实践声明	一般原则
良好实践声明1	为规范BPSD的结构化评估及临床管理路径,建议为临床医护人员与非专业照护者提供多维度教育培训。
良好实践声明2	征得患者或患者家属的知情同意。
良好实践声明3	将患者价值观、个体化照护目标及预计恢复前景等核心要素纳入结构化评估体系。
良好实践声明4	回顾痴呆症的潜在病因、痴呆症的分期(轻度、中度、重度)及特征性BPSD,包括发生频率、持续时间、严重程度及其他可能相关的危险因素。
良好实践声明5	对BPSD潜在生物学诱因进行系统评估,包括谵妄状态评估、综合医学评估及精神病史采集、药物使用情况审查、物质使用情况调查、听力与视力功能评估、疼痛程度评估及其他相关生物医学因素分析。
良好实践声明6	对痴呆症患者的人格特征进行全面审查,包括性别、性取向、语言、种族、民族、文化背景、外伤史、宗教或精神信仰以及其他相关因素,从而深度解析BPSD的潜在影响因素,为评估和管理BPSD提供依据。
良好实践声明7	构建基于生物-心理-社会医学模式的BPSD全面评估体系。
良好实践声明8	在与痴呆症患者、护理人员或医疗保健提供者交流时,采用以人为本的表达方式,并根据受众特点,用通俗易懂的语言具体描述BPSD。
良好实践声明9	建议对所有BPSD患者单独实施社会心理干预,或结合药物治疗进行综合治疗。
良好实践声明10	针对特定BPSD(行为与心理症状),选择并调整安全有效的干预措施。
良好实践声明11	定期评估BPSD管理计划的有效性,并根据动态评估指标对干预措施进行优化调整。